Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

L. J. Ma, C. Marcantoni, M. F. Linton, Sergio Fazio, A. B. Fogo

Research output: Contribution to journalArticle

169 Citations (Scopus)

Abstract

Background. Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcriptional factors with beneficial effects in diabetes mediated by improved insulin sensitivity and lipid metabolism, but potential adverse effects in atherosclerosis by promoting in vitro foam cell formation. We explored whether a PPARγ agonist, troglitazone (TGL), affects sclerosis by mechanisms unrelated to insulin and lipid effects in a model of nondiabetic glomerulosclerosis. Methods. Adult male Sprague Dawley rats underwent 5/6 nephrectomy and were treated for 12 weeks as follows: Control (CONT), no further treatment; triple antihypertensive therapy (TRX); and TGL or TGL + TRX, Functional, morphological, and molecular analyses were performed, Results. Systolic blood pressure (SBP) was increased in CONT and TGL groups (161 ± 1 and 160 ± 3 mm Hg), but not in TGL + TRX and TRX (120 ± 3 vs. 126 ± 1 mm Hg, P <0,0001 vs. non-TRX). Serum triglyceride and cholesterol levels in all groups remained normal except for slightly higher serum cholesterol levels in TRX group. TGL groups had reduced proteinuria, serum creatinine, and glomerulosclerosis versus CONT, in contrast to no significant effect with TRX alone (sclerosis index, 0 to 4+ scale: CONT 1.99 ± 0.42, TGL 0.85 ± 0.12, TGL + TRX 0.56 ± 0.14, TRX 1.30 ± 0.21; TGL, P <0.05; TGL + TRX, P = 0.01 vs. CONT). Glomerular cell proliferation, assessed by proliferating cell nuclear antigen (PCNA), was decreased alter treatment with TGL or TGL + TRX, in parallel with decreases in glomerular p21 mRNA and p27 protein compared with CONT and TRX (PCNA + cells/glomerulus: CONT 2.04 ± 0.64, TGL 0.84 ± 0.21, TGL + TRX 0.30 ± 0.07, TRX 1.38 ± 0.37; TGL, P <0.05, TGL + TRX, P <0.01 vs. CONT). Glomerular plasminogen activator inhibitor-1 (PAI-1) immunostaining was decreased in TGL or TGL + TRX groups (0 to 4+ scale, CONT 2.42 ± 0.32, TGL 1.40 ± 0.24, TGL + TRX 1.24 ± 0.17, TRX 2.53 ± 0.24; TGL or TGL + TRX vs. CONT, P <0.05), with a parallel decrease in PAI-1 mRNA by in situ hybridization. Glomerular and tubular transforming growth factor-β (TGF-β) mRNA expression was decreased with TGL treatment, Glomerular macrophages, present in CONT and TRX rats, did not express PPARγ, in contrast to PPARγ + macrophages in control carotid artery plaque, PPARγ was expressed in resident cells. Conclusions. Our results demonstrate in vivo that the PPARγ ligand TGL ameliorates the progression of glomerulosclerosis in a nondiabetic model. Macrophages show phenotypic diversity in glomerular versus vascular sclerosis, with macrophage PPARγ expression in only the latter. PPARγ beneficial effects are independent of insulin/glucose effects and are associated with regulation of glomerular cell proliferation, hypertrophy, and decreased PAI-1 and TGF-β expression.

Original languageEnglish (US)
Pages (from-to)1899-1910
Number of pages12
JournalKidney International
Volume59
Issue number5
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

troglitazone
Peroxisome Proliferator-Activated Receptors
Plasminogen Activator Inhibitor 1
Macrophages

Keywords

  • Cell turnover
  • Macrophage
  • p21
  • p27
  • Plasminogen activator inhibitor-1

ASJC Scopus subject areas

  • Nephrology

Cite this

Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats. / Ma, L. J.; Marcantoni, C.; Linton, M. F.; Fazio, Sergio; Fogo, A. B.

In: Kidney International, Vol. 59, No. 5, 2001, p. 1899-1910.

Research output: Contribution to journalArticle

@article{571775fb497e4b2cb7a2a1c213de7f30,
title = "Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats",
abstract = "Background. Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcriptional factors with beneficial effects in diabetes mediated by improved insulin sensitivity and lipid metabolism, but potential adverse effects in atherosclerosis by promoting in vitro foam cell formation. We explored whether a PPARγ agonist, troglitazone (TGL), affects sclerosis by mechanisms unrelated to insulin and lipid effects in a model of nondiabetic glomerulosclerosis. Methods. Adult male Sprague Dawley rats underwent 5/6 nephrectomy and were treated for 12 weeks as follows: Control (CONT), no further treatment; triple antihypertensive therapy (TRX); and TGL or TGL + TRX, Functional, morphological, and molecular analyses were performed, Results. Systolic blood pressure (SBP) was increased in CONT and TGL groups (161 ± 1 and 160 ± 3 mm Hg), but not in TGL + TRX and TRX (120 ± 3 vs. 126 ± 1 mm Hg, P <0,0001 vs. non-TRX). Serum triglyceride and cholesterol levels in all groups remained normal except for slightly higher serum cholesterol levels in TRX group. TGL groups had reduced proteinuria, serum creatinine, and glomerulosclerosis versus CONT, in contrast to no significant effect with TRX alone (sclerosis index, 0 to 4+ scale: CONT 1.99 ± 0.42, TGL 0.85 ± 0.12, TGL + TRX 0.56 ± 0.14, TRX 1.30 ± 0.21; TGL, P <0.05; TGL + TRX, P = 0.01 vs. CONT). Glomerular cell proliferation, assessed by proliferating cell nuclear antigen (PCNA), was decreased alter treatment with TGL or TGL + TRX, in parallel with decreases in glomerular p21 mRNA and p27 protein compared with CONT and TRX (PCNA + cells/glomerulus: CONT 2.04 ± 0.64, TGL 0.84 ± 0.21, TGL + TRX 0.30 ± 0.07, TRX 1.38 ± 0.37; TGL, P <0.05, TGL + TRX, P <0.01 vs. CONT). Glomerular plasminogen activator inhibitor-1 (PAI-1) immunostaining was decreased in TGL or TGL + TRX groups (0 to 4+ scale, CONT 2.42 ± 0.32, TGL 1.40 ± 0.24, TGL + TRX 1.24 ± 0.17, TRX 2.53 ± 0.24; TGL or TGL + TRX vs. CONT, P <0.05), with a parallel decrease in PAI-1 mRNA by in situ hybridization. Glomerular and tubular transforming growth factor-β (TGF-β) mRNA expression was decreased with TGL treatment, Glomerular macrophages, present in CONT and TRX rats, did not express PPARγ, in contrast to PPARγ + macrophages in control carotid artery plaque, PPARγ was expressed in resident cells. Conclusions. Our results demonstrate in vivo that the PPARγ ligand TGL ameliorates the progression of glomerulosclerosis in a nondiabetic model. Macrophages show phenotypic diversity in glomerular versus vascular sclerosis, with macrophage PPARγ expression in only the latter. PPARγ beneficial effects are independent of insulin/glucose effects and are associated with regulation of glomerular cell proliferation, hypertrophy, and decreased PAI-1 and TGF-β expression.",
keywords = "Cell turnover, Macrophage, p21, p27, Plasminogen activator inhibitor-1",
author = "Ma, {L. J.} and C. Marcantoni and Linton, {M. F.} and Sergio Fazio and Fogo, {A. B.}",
year = "2001",
doi = "10.1046/j.1523-1755.2001.0590051899.x",
language = "English (US)",
volume = "59",
pages = "1899--1910",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Peroxisome proliferator-activated receptor-γ agonist troglitazone protects against nondiabetic glomerulosclerosis in rats

AU - Ma, L. J.

AU - Marcantoni, C.

AU - Linton, M. F.

AU - Fazio, Sergio

AU - Fogo, A. B.

PY - 2001

Y1 - 2001

N2 - Background. Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcriptional factors with beneficial effects in diabetes mediated by improved insulin sensitivity and lipid metabolism, but potential adverse effects in atherosclerosis by promoting in vitro foam cell formation. We explored whether a PPARγ agonist, troglitazone (TGL), affects sclerosis by mechanisms unrelated to insulin and lipid effects in a model of nondiabetic glomerulosclerosis. Methods. Adult male Sprague Dawley rats underwent 5/6 nephrectomy and were treated for 12 weeks as follows: Control (CONT), no further treatment; triple antihypertensive therapy (TRX); and TGL or TGL + TRX, Functional, morphological, and molecular analyses were performed, Results. Systolic blood pressure (SBP) was increased in CONT and TGL groups (161 ± 1 and 160 ± 3 mm Hg), but not in TGL + TRX and TRX (120 ± 3 vs. 126 ± 1 mm Hg, P <0,0001 vs. non-TRX). Serum triglyceride and cholesterol levels in all groups remained normal except for slightly higher serum cholesterol levels in TRX group. TGL groups had reduced proteinuria, serum creatinine, and glomerulosclerosis versus CONT, in contrast to no significant effect with TRX alone (sclerosis index, 0 to 4+ scale: CONT 1.99 ± 0.42, TGL 0.85 ± 0.12, TGL + TRX 0.56 ± 0.14, TRX 1.30 ± 0.21; TGL, P <0.05; TGL + TRX, P = 0.01 vs. CONT). Glomerular cell proliferation, assessed by proliferating cell nuclear antigen (PCNA), was decreased alter treatment with TGL or TGL + TRX, in parallel with decreases in glomerular p21 mRNA and p27 protein compared with CONT and TRX (PCNA + cells/glomerulus: CONT 2.04 ± 0.64, TGL 0.84 ± 0.21, TGL + TRX 0.30 ± 0.07, TRX 1.38 ± 0.37; TGL, P <0.05, TGL + TRX, P <0.01 vs. CONT). Glomerular plasminogen activator inhibitor-1 (PAI-1) immunostaining was decreased in TGL or TGL + TRX groups (0 to 4+ scale, CONT 2.42 ± 0.32, TGL 1.40 ± 0.24, TGL + TRX 1.24 ± 0.17, TRX 2.53 ± 0.24; TGL or TGL + TRX vs. CONT, P <0.05), with a parallel decrease in PAI-1 mRNA by in situ hybridization. Glomerular and tubular transforming growth factor-β (TGF-β) mRNA expression was decreased with TGL treatment, Glomerular macrophages, present in CONT and TRX rats, did not express PPARγ, in contrast to PPARγ + macrophages in control carotid artery plaque, PPARγ was expressed in resident cells. Conclusions. Our results demonstrate in vivo that the PPARγ ligand TGL ameliorates the progression of glomerulosclerosis in a nondiabetic model. Macrophages show phenotypic diversity in glomerular versus vascular sclerosis, with macrophage PPARγ expression in only the latter. PPARγ beneficial effects are independent of insulin/glucose effects and are associated with regulation of glomerular cell proliferation, hypertrophy, and decreased PAI-1 and TGF-β expression.

AB - Background. Peroxisome proliferator-activated receptor-γ (PPARγ) is a member of the nuclear receptor superfamily of ligand-dependent transcriptional factors with beneficial effects in diabetes mediated by improved insulin sensitivity and lipid metabolism, but potential adverse effects in atherosclerosis by promoting in vitro foam cell formation. We explored whether a PPARγ agonist, troglitazone (TGL), affects sclerosis by mechanisms unrelated to insulin and lipid effects in a model of nondiabetic glomerulosclerosis. Methods. Adult male Sprague Dawley rats underwent 5/6 nephrectomy and were treated for 12 weeks as follows: Control (CONT), no further treatment; triple antihypertensive therapy (TRX); and TGL or TGL + TRX, Functional, morphological, and molecular analyses were performed, Results. Systolic blood pressure (SBP) was increased in CONT and TGL groups (161 ± 1 and 160 ± 3 mm Hg), but not in TGL + TRX and TRX (120 ± 3 vs. 126 ± 1 mm Hg, P <0,0001 vs. non-TRX). Serum triglyceride and cholesterol levels in all groups remained normal except for slightly higher serum cholesterol levels in TRX group. TGL groups had reduced proteinuria, serum creatinine, and glomerulosclerosis versus CONT, in contrast to no significant effect with TRX alone (sclerosis index, 0 to 4+ scale: CONT 1.99 ± 0.42, TGL 0.85 ± 0.12, TGL + TRX 0.56 ± 0.14, TRX 1.30 ± 0.21; TGL, P <0.05; TGL + TRX, P = 0.01 vs. CONT). Glomerular cell proliferation, assessed by proliferating cell nuclear antigen (PCNA), was decreased alter treatment with TGL or TGL + TRX, in parallel with decreases in glomerular p21 mRNA and p27 protein compared with CONT and TRX (PCNA + cells/glomerulus: CONT 2.04 ± 0.64, TGL 0.84 ± 0.21, TGL + TRX 0.30 ± 0.07, TRX 1.38 ± 0.37; TGL, P <0.05, TGL + TRX, P <0.01 vs. CONT). Glomerular plasminogen activator inhibitor-1 (PAI-1) immunostaining was decreased in TGL or TGL + TRX groups (0 to 4+ scale, CONT 2.42 ± 0.32, TGL 1.40 ± 0.24, TGL + TRX 1.24 ± 0.17, TRX 2.53 ± 0.24; TGL or TGL + TRX vs. CONT, P <0.05), with a parallel decrease in PAI-1 mRNA by in situ hybridization. Glomerular and tubular transforming growth factor-β (TGF-β) mRNA expression was decreased with TGL treatment, Glomerular macrophages, present in CONT and TRX rats, did not express PPARγ, in contrast to PPARγ + macrophages in control carotid artery plaque, PPARγ was expressed in resident cells. Conclusions. Our results demonstrate in vivo that the PPARγ ligand TGL ameliorates the progression of glomerulosclerosis in a nondiabetic model. Macrophages show phenotypic diversity in glomerular versus vascular sclerosis, with macrophage PPARγ expression in only the latter. PPARγ beneficial effects are independent of insulin/glucose effects and are associated with regulation of glomerular cell proliferation, hypertrophy, and decreased PAI-1 and TGF-β expression.

KW - Cell turnover

KW - Macrophage

KW - p21

KW - p27

KW - Plasminogen activator inhibitor-1

UR - http://www.scopus.com/inward/record.url?scp=0035046542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035046542&partnerID=8YFLogxK

U2 - 10.1046/j.1523-1755.2001.0590051899.x

DO - 10.1046/j.1523-1755.2001.0590051899.x

M3 - Article

C2 - 11318962

AN - SCOPUS:0035046542

VL - 59

SP - 1899

EP - 1910

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -